Rivastigmine tartrate is suggested for treatment of mild to moderate Alzheimer’s dementia and mild to moderate Parkinson’s disease dementia.
Caraco Pharma Rivastigmine tartrate capsules are available in 1.5mg, 3mg, 4.5mg and 6mg strengths.
Rivastigmine is said to have demonstrated treatment effects on the cognitive (thinking and memory), functional (activities of daily living) and behavioural problems that are commonly associated with Alzheimer’s and Parkinson’s disease dementias.
Rivastigmine tartrate capsules, approved by FDA for Sun Pharma’s abbreviated new drug application (ANDA), are therapeutically equivalent to Novartis Exelon capsules.